show that this pro-apoptotic effect can be overcome using a strong costimulatory signal that prevents activation-induced cell death and enables low avidity T cells to traffic into the tumor and assist in tumor clearance. These findings identify new therapeutic opportunities for activating the most potent anticancer T cell responses.
Abstract
A major barrier of vaccines as cancer treatment is their failure to activate and maintain a complete cancer-specific CD8 + effector T cell repertoire. Low avidity T cells are more likely to escape clonal deletion in the thymus when compared to higher avidity T cells, and therefore comprise the major population of effector T cells available for activation in cancer patients. However, low avidity T cells fail to traffic into the tumor microenvironment and function in eradicating tumor under optimal vaccination conditions as opposed to higher avidity T cells that escape clonal deletion and function in tumor-killing. We utilized high and low avidity TCR transgenic CD8 show that this pro-apoptotic effect can be overcome using a strong costimulatory signal that prevents activation-induced cell death and enables low avidity T cells to traffic into the tumor and assist in tumor clearance. These findings identify new therapeutic opportunities for activating the most potent anticancer T cell responses.
Introduction
Cancer vaccines that activate cytotoxic CD8 + T cells are emerging as a promising treatment for patients with cancer (1) . Vaccines are most effective when they induce a large higher-avidity T cell repertoire with populations specific for multiple epitopes of relevant tumor antigens (2) . However, one barrier to effective immunization is the predominant establishment of lower avidity and therefore less potent T cells instead of the high avidity T cells typically found in non tumor-bearing hosts. This scarcity of high avidity T cells is due to clonal deletion during thymic selection, from which the low avidity T cells are capable of escaping (3, 4) . This results in a population of low avidity T cells available in the periphery to mount a potential antitumor response (3, 4) . While thymic deletion is an important mechanism to protect the host from the activation of selfreactive T cells, the remaining lower avidity T cells have a higher threshold of activation and are greatly impaired by the peripheral tolerance mechanisms (5-7).
A second barrier to effective activation of both high and low avidity T cells are the many cell types within the tumor microenvironment, including the tumor cells themselves, which inactivate vaccine-induced tumor-targeted T cells. Both high avidity and low avidity T cells are regulated by multiple peripheral tolerance mechanisms including suppression by regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and intrinsic T cell tolerance mechanisms such as anergy that result in increased expression of co-inhibitory molecules including cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death receptor-1 (PD-1) (6, (8) (9) (10) . Low avidity T cells are also subject to peripheral deletion triggered by the chronic presence of small amounts of antigen, but can either escape deletion when no antigen is present or be protected against deletion through activation or anergy if they receive a strong enough TCR signal (6) . While high and low avidity T cells may be regulated by similar mechanisms, emerging evidence suggest that there are also signaling pathways that predominantly regulate low versus high avidity populations within the T cell repertoire (8, (11) (12) (13) (14) (15) . Agents are being developed that can modulate a number of these T cell regulatory pathways leading to enhanced antitumor activity in preclinical models and in patients with cancer (11, 12, (16) (17) (18) (19) . The first such agent, ipilimumab (Yervoy), was recently approved for use by the US FDA for its ability to activate T cells by downregulating the T cell inhibitory signal CTLA-4 in patients with metastatic melanoma (20) .
It is still not clear which signaling pathways regulate low versus high avidity T cells and whether it is possible to convert a low avidity T cell into one that functions with high avidity potency. Thus, understanding the activation signaling differences between high and low avidity T cells will facilitate the discovery of additional drugs that activate a more complete T cell repertoire.
We previously reported the development of high and low avidity CD8 + T cell populations specific for the same HER-2/neu-expressing (21) immunodominant epitope, RNEU 420-429 (22) . These TCR transgenic mice were used to identify a sub-population of Tregs that inhibit high avidity T cells from functioning within the tumor. In addition, immune-modulating doses of cyclophosphamide (23) given with a neu-targeted, GM-CSF-secreting vaccine inhibit these Tregs and allow for complete eradication of neuexpressing mammary tumors by adoptively transferred high avidity T cells (24) . In contrast, adoptively transferred low avidity T cells fail to traffic into and eradicate the tumor under the same conditions (22) . Using these two TCR transgenic T cell 5 populations, we show for the first time that low avidity T cells have increased expression of the pro-apoptotic proteins TNFRSF10B (DR5), FasL, and CD24; and the expression of these proteins correlates with reduced T cell function and increased T cell death. In addition, the presence of FasL-expressing low avidity T cells also causes death of high avidity CD8 + T cells when co-cultured in vitro. These studies establish that blocking activation-induced cell death (AICD) with TNF-receptor agonists (anti-OX40 and 41BB antibodies) allows low avidity T cells to traffic into the tumor and enhance tumor clearance. Therefore, these data identify the death receptors as a new mechanism responsible for regulating low avidity CD8 + T cell populations, providing new opportunities for developing another class of immune-modulating agents that can enhance the activity of cancer vaccines.
Materials and Methods

Mice
HER-2/neu (neu-N) transgenic mice were purchased from Jackson Laboratory (FVB-Tg(MMTV-Erbb2)NK1Mul/J), and bred and housed at the Johns Hopkins animal facility. Experiments were performed using female mice between 6 and 12 weeks old and protocols approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine. High and low avidity T cell receptor (TCR) transgenic mice were generated from RNEU 420-429 specific T cell clones as described (22) .
Dilutional tetramer staining was used to verify the avidity of each mouse before use.
Cell lines and Media
The NT2.5 tumor cell line, 3T3neuGM vaccine, 3T3GM mock vaccine, and T2-D q T cell target cell line were created and maintained as previously reported (25). GM-CSF was verified by ELISA and neu levels were verified by flow cytometry bi-annually (25).
Peptides and Antibodies
The immunodominant RNEU 420-429 (PDSLRDLSVF) peptide and LCMV NP [118] [119] [120] [121] [122] [123] [124] [125] [126] (RPQASGVYM) negative control peptide were synthesized at >95% purity in the Johns Hopkins Biosynthesis and Sequencing Facility. The anti-OX40 antibody was produced from the OX86 hybridoma, a gift from the Weinberg lab. The hybridoma was grown in protein-free hybridoma media (Gibco) and purified over a protein G column (BD Pharmingen). Purified rat IgG was used as an irrelevant control (Jackson Laboratories). Proliferation was assessed using the CellTrace CFSE cell proliferation kit (Invitrogen). 300μg of OX40 or 41BB antibody (R&D) was given i.p. with adoptive transfer three and seven days after vaccination. 300ug of CD4 + T cell-depletion antibody (Biolegend) was given i.p. three days before adoptive transfer. All experiments described in this paper were repeated at least twice with a minimum of 3 mice per group.
Intracellular cytokine staining (26) and flow cytometry
Three days after adoptive transfer, intracellular staining was performed on cells from tumor-draining lymph nodes using the mouse intracellular staining kit (BD Biosciences). 1x10 were read on an LSR-II flow cytometer and analyzed using FACSDiva software (BD Biosciences). Tumor-infiltrating lymphocytes were analyzed by surface staining 5 days after adoptive transfer. Tumors were mashed and digested using 1mg/ml collagenase (Gibco) and 25μg/ml hyaluronidase (Sigma) before being stained and analyzed by flow cytometry. 
Tumor-treatment studies
Apoptosis studies
T cells were isolated as described above from tumor-draining lymph nodes on day 3 and stained for surface markers before staining with Annexin V and 7-AAD (7-aminoactinomycin D) as described in BD Biosciences' Apoptosis Detection Kit. Crosslinking apoptosis studies were performed in vitro on splenocytes from high and low avidity TCR transgenic mice by adding 0.1μg/ml purified Fas antibody, 500ng/ml CD24 antibody, or 500ng/ml IgG to 5×10 
Procedure for low avidity T cell killing of high avidity T cells
Results
Cell death proteins are upregulated in low avidity CD8 + T cells relative to high avidity T cells in tolerant mice
We previously reported that vaccinated, Cy-treated low avidity RNEU 420-429 -specific TCR transgenic T cells adoptively transferred into a tolerant environment do not clear tumor, whereas similarly treated high avidity T cells also specific for RNEU [420] [421] [422] [423] [424] [425] [426] [427] [428] [429] are capable of clearing large burdens of tumor (22) . Low avidity T cells also do not secrete effector cytokines characteristic of fully activated T cells nor do they traffic to the tumor (22) . To explain this disparity in functionality we adoptively transferred naive low and high avidity TCR transgenic T cells into neu-N transgenic mice to identify differences in protein expression between high and low avidity T cells in a tolerant environment. CD8 + T cells were adoptively transferred into tumor-bearing neu-N mice treated with vaccine+Cy and isolated from the tumor-draining lymph nodes of the neu-N mice 3 days after adoptive transfer (22) . mRNA was extracted from these cells to perform microarray analysis of gene expression (Fig. S1 ). Ingenuity analysis of microarray data identified cell death pathways significantly increased in low versus high avidity T cells. Flow cytometry studies further confirmed that the pro-death proteins DR5, FasL, and CD24 are expressed at higher levels on low avidity cells than high avidity cells (Fig. 1A-C) . These initial studies led to the hypothesis that higher expression of pro-death proteins on low avidity T cells may explain the difference in function between low and high avidity T cells in a tolerant tumor microenvironment. (22) .
To determine the effect of DR5, FasL, and CD24 on the function of low avidity T cells we first compared the expression of these proteins with IFNγ secretion. Low avidity T cells that express DR5, FasL, and CD24 secrete even less IFNγ than low avidity T cells that do not express these proteins ( Fig. 2A) . T cell trafficking into tumors is another important function of activated cancer-specific T cells.
As mentioned before, low avidity T cells do not traffic into the tumor even in mice treated with Cy plus vaccine, whereas high avidity T cells do traffic into and eradicate large burdens of neu-expressing tumors in mice treated with Cy plus vaccine. We therefore evaluated whether there is differential expression of death-associated proteins on high avidity T cells that traffic into the tumor versus those that do not. Analysis of these high avidity tumor-infiltrating lymphocytes showed significantly lower expression of DR5, FasL, and CD24 on cells that traffic into the tumor when compared to cells that remained in the tumor-draining lymph nodes (Fig. 2B ). These proteins are also more highly expressed on low avidity T cells activated in vivo or in vitro than naïve cells (Fig.   S2 ). Annexin V and 7AAD staining confirmed that DR5, FasL, and CD24 protein expression is upregulated on apoptosing T cells (Fig. 2C) . The finding that T cells expressing DR5, FasL, and CD24 secrete less IFNγ and are less likely to traffic into tumors indicate that T cells expressing these death receptor proteins are less functional as antitumor effector cells than cells that do not express these proteins.
FasL expression on apoptosis-sensitive low avidity T cells also causes increased apoptosis of high avidity T cells
To determine whether low avidity T cells expressing these death receptors are more susceptible to cell death as our initial studies suggest we used an anti-Fas receptor antibody. 1x10 (Fig. 3A) . CD24-mediated low avidity T cell death was also verified by antibody crosslinking of CD24 (Fig. 3B) .
Since vaccination induces a polyclonal T cell repertoire with a range of avidities specific for a tumor antigen, we wanted to address whether low avidity T cells could 
with RNEU 420-429 peptide, with and without low avidity T cells. We found that apoptosis does increase in high avidity T cells when stimulated in the presence of low avidity T cells (Fig. 3C ). In addition, we found that blocking the Fas/FasL interaction on high avidity T cells with a FasL blocking antibody prevented the increase in high avidity T cell apoptosis. This indicates that low avidity T cells cause death of high avidity T cells in a Fas-dependent manner. These studies demonstrate that not only are low avidity T cells more susceptible to death themselves but they are also able to induce cell death in other tumor-specific T cell populations. 
and IgG failed to traffic into the tumors (Fig. 4B) . Low avidity T cells from the tumordraining nodes of mice treated with anti-OX40 antibody also had decreased expression of DR5, CD24, and FasL (Fig. 4C) . The percent of dead cells was also significantly lower in the anti-OX40-treated group in comparison to the IgG-treated group (Fig. 4D) .
Furthermore, increased cytokine activity and trafficking function exhibited by low avidity T cells treated with Cy+vaccine+anti-OX40 antibody resulted in increased tumor-free survival when compared with mice treated with either Cy+vaccine+IgG, antiOX40+vaccine alone without Cy, or anti-OX40+Cy+mock vaccine (Fig. 4E) . AntiOX40+vaccine+Cy-treated mice were also able to eradicate 10% of established tumors (Fig. S3) .
Two mechanisms by which treatment with anti-OX40 antibody prevents cell death are increased expression of anti-apoptotic proteins Bcl-2 and survivin (Fig. 4F ).
Survivin expression is significantly increased in anti-OX40+Cy+vaccine-treated mice on Peripheral deletion occurs when T cells are exposed to a weak TCR signal without the proper costimulation (7). T cells that do not encounter antigen survive without being activated and are non-functional, whereas T cells that receive a weak TCR signal are susceptible to peripheral deletion and T cells that receive a strong TCR signal are activated. We confirmed this finding by comparing cell survival between untreated, vaccinated, and OX40-treated mice (Fig. S4) . Because low avidity T cells are more likely to be present in the periphery of tumor-bearing mice than high avidity T cells but were identified as being more susceptible to cell death, we wanted to determine if the amount of antigen exposure was contributing to the death of low avidity T cells. To test this, we compared untreated mice with Cy+vaccine-treated tumor-bearing mice where the vaccine provides an antigen source for low avidity T cells. We found that the percent of apoptosing T cells was increased in the spleen of tumor-bearing treated mice when compared to non-tumor-bearing untreated mice (Fig. 5A) . We also found that giving the Cy+vaccine-treated neu-N mice anti-OX40 antibody reduced the amount of low avidity T cell death to equivalent levels observed in untreated non-tumor-bearing mice (Fig. 5A ).
These data suggest that low avidity T cell apoptosis is facilitated by the presence of T cell-specific antigens in the context of a T cell-alerting vaccine. In vitro, low avidity T cells incubated with T2 cells pulsed with increasing amounts of peptide demonstrated that increased peptide stimulation led to increased low avidity T cell death (Fig. 5B) . We also found that low avidity T cell death increases upon proliferation (likely a consequence of the T cell-alerting vaccine), with increased proliferation leading to increased cell death (Fig. 5C) . This proliferating population of T cells most likely to apoptose is also the population with the highest expression of pro-apoptotic proteins and potential to secrete IFNγ (Fig. 5D and 5E ), both are likely consequences of the vaccine's attempt to activate these T cells. These studies demonstrate that low avidity T cells are susceptible to apoptosis after vaccine activation, and that the terminally divided group of low avidity T cells most likely to be functionally active is also the group most likely to express proapoptotic proteins and be susceptible to cell death. OX40 treatment can rescue this low avidity T cell population from cell death allowing these T cells to sustain functional activity.
Increase in low avidity T cell function by anti-OX40 treatment is independent of CD4 + T cell help
To further evaluate the mechanism by which anti-OX40 agonistic antibody augments low avidity T cell function, we evaluated whether CD4 (Fig. 6A) . To confirm that anti-OX40 treatment lead to increased function of low avidity T cells through increased co-stimulation of the TNF receptor (death receptor) pathway, agonistic 41BB-specific co-stimulation was also tested since it is also a member of this family of death receptor agonists. Cy-treated and vaccinated neu-N mice given anti-41BB also demonstrated increased low avidity T cell function as measured by IFNγ secretion and tumor-trafficking (Fig. 6B-C) . Anti-41BB was also able to eradicate established tumors We recently reported that adoptively transferred high avidity T cells require both an antigen-specific vaccination and Treg inhibitors to achieve long-term eradication of progressing murine tumors in neu-N mice (22) . That study also reported that low avidity T cells were ineffective under these conditions. This paper demonstrates that this lack of function can be overcome with TNFR agonists, which has important implications for the treatment of cancer patients.
The TNFR agonists used in this study to improve the function of low avidity T cells were agonistic anti-OX40 and -41BB antibodies. OX40 is a costimulatory molecule that is able to protect cells from AICD (27) (28) (29) (30) . Both OX40 and 41BB have been shown to provide a more efficient antitumor response (32) . This is in direct agreement with our findings that OX40 agonists can allow non-trafficking tumor specific T cells to traffic to the tumor. It has also been shown that OX40 can help T cells overcome tolerance and reverse anergy (33, 34) . Our previously published work demonstrated an improved antitumor response in neu-N mice when an OX40 agonist is combined with vaccine treatment (33) . That study looked at the endogenous population of CD8 + T cells as opposed to using adoptively transferred T cells of known avidities as we did in this work.
In addition to OX40 agonists, 41BB agonists have also been shown to increase T cell function and survival (35) (36) (37) (38) . Hernandez-Chacon et al. demonstrated that 41BB agonists could protect melanoma TILs from AICD (36) . While this study again is unrelated to avidity, it supports our study results demonstrating that T cells trafficking into the tumor benefit from 41BB agonists. Eliminating established tumors with OX40 and 41BB was performed to determine the mechanism that increases the function of low avidity T cells and not to compare the efficacy of 41BB agonists to OX40 agonists. The eventual reestablishment of tumors is not surprising since only one dose was given. While many studies show the benefits of TNFR agonists on tumor-specific T cells, our study is the first to elucidate a specific mechanism showing a direct effect on low avidity antigenspecific T cells.
41BB and OX40 antibody treatments have been shown to increase the expression of the anti-apoptotic protein Bcl-2 (36, 39). OX40 has also been shown to increase the expression of another anti-apoptotic protein, survivin, resulting in T cell proliferation and expansion (30) . These findings are important because they demonstrate the link between the TNFR agonists and the mechanism these death receptors are using to prevent death. 
As in those studies, our study found that Bcl-2 and survivin expression were increased on low avidity T cells with OX40 mAb treatment, overcoming the effects of the proapoptotic proteins highly expressed on neu-specific low avidity T cells. Our data also show that OX40 is not affecting CD8 The discovery that TNFR agonists enable low avidity T cells to effectively eradicate tumor was a direct result of the major novel finding in this study that low avidity T cells are ineffective at tumor-trafficking and -killing due to their early cell death upon activation. This finding is significant because the first step to engaging low avidity T cell populations in eradicating tumors is to identify the mechanism(s) that cause them to be nonfunctional. In this study, low avidity T cells were found to be specifically vulnerable to cell death due to the increased expression of three pro-apoptotic proteins: DR5, CD24, and FasL. Our study found that TNFR agonists reduce the expression of these pro-apoptotic proteins. Due to early upregulation of the death receptors upon T cell activation in our mouse model we were unable to alter the function of low avidity T The increased expression of FasL on low avidity T cells that was found by our study is noteworthy because death by ligation of Fas/FasL is the main pathway for AICD, the mechanism for peripheral deletion (45) (46) (47) . In addition to causing autonomous death of the T cell itself, FasL expression also causes death in Fas-expressing neighboring T cells (48) . Thus, another novel finding by our study was that not only were low avidity T cells more susceptible to cell death, but the presence of low avidity tumor-specific T cells led to Fas-dependent cell death of high avidity tumor-specific T cells. This finding indicates that low avidity T cells could potentially be regulating high avidity T cells and be an additional factor contributing to the suppressive environment causing a lack of tumor immunogenicity. These data also suggest that agents that only aim to activate high avidity T cells may not achieve optimal activity if low avidity T cells are not also non-tumor-bearing mice, and that low avidity T cells have increased death upon exposure to increased amounts of peptide. These data confirm and expand the results of Redmond and colleagues demonstrating increased numbers of surviving T cells when adoptively transferred without peptide transfer (6, 7) . Interestingly, our data showed that this death is in the population of divided cells, which may express pro-apoptotic proteins or secrete IFNγ. These results are significant because they suggest that tumor-specific low avidity T cells are dying upon exposure to antigen and initial activation signals, which has not been reported. In fact, one study reported that lower avidity CD4 + GAD-specific autoreactive T cells were actually less susceptible to AICD (49) , but that study was performed under completely different activation conditions than ours.
In conclusion, these studies establish that low avidity T cells are not inherently ineffective, and that blocking AICD with costimulatory signals through the TNF receptor antibody also increases low avidity T cell function. Tumor-bearing, Cy-and vaccinetreated neu-N mice were given anti-OX40, anti-OX40 and CD4-depleting antibody, or 41BB antibody and cells were extracted for analysis three days after low avidity T-cell adoptive transfer for analysis of cytokine secretion and five days after adoptive transfer for trafficking information. OX40 and 41BB were both given at doses of 300μg on the day of adoptive transfer with OX40 again being given three days after adoptive transfer to mice being analyzed for trafficking. These experiments were repeated at least 3 times 
